Company Overview and News

 
Corona Remedies acquires two brands from Abbott

2018-04-02 moneycontrol
City-based pharma firm Corona Remedies today announced the acquisition of Obimet and Thyrocab brands, comprising of 14 product line extensions, from Abbott India.
Upvote Downvote

 
In ₹1,000-crore deal, SEBI buys IDBI Bank’s Mumbai property

2018-02-12 thehindubusinessline
In one of India’s biggest commercial property acquisitions, market regulator SEBI has struck a deal to buy IDBI Bank’s seven-storey office building at the Bandra-Kurla Complex (BKC), Mumbai’s prime business hub.
Upvote Downvote

 
Market Update: Midcap index outshines; Tata Steel, ONGC jump 3-4%; Ashok Leyland hits new 52-week high, SBI falls 3%

2018-02-12 moneycontrol
A new week and a new start - it was a green opening from the Indian indices with the Sensex jumping over 256 points or 0.75 percent in early trade while the Nifty added 73 points or 0.72 percent.
Upvote Downvote

 
Govt stalls plan to cut drug prices after pushback from pharma companies

2018-01-12 business-standard
Ari Altstedter & Abhijit Roy Chowdhury | Bloomberg  Last Updated at January 12, 2018 18:01 IST
Upvote Downvote

 
Market Update: Unitech zooms 20%; HDFC Bank jumps 2%; Vedanta top gainer, Airtel most active

2017-12-08 moneycontrol
The Indian benchmark indices on Friday afternoon were trading on a positive note with the Nifty up 82 points or 0.81 percent while the Sensex added 254 points and was trading at 33203.
Upvote Downvote

 
Market Update: 115 stocks hit new 52-week high on BSE; Maruti top gainer, ICICI Bank up 1%

2017-12-08 moneycontrol
The Indian benchmark indices on Friday afternoon were trading on a positive note with the Nifty up 76 points or 0.75 percent while the Sensex added 241 points and was trading at 33190.
Upvote Downvote

 
Market Update: Maruti hits new record high, Future Consumer zooms 14%; DLF hits 52-week high

2017-12-08 moneycontrol
The Indian benchmark indices on Friday morning were trading on a positive note with the Nifty up 61 points or 0.6 percent while the Sensex added 198 points and was trading at 33151.
Upvote Downvote

 
Market Update: SBI, PNB, YES Bank up 2% as Bank Nifty outperforms; Hero Moto, Wipro top losers

2017-12-05 moneycontrol
The Indian benchmark indices on Tuesday afternoon were still trading on a negative note with the Nifty up 1 point or 0.01 percent while the Sensex shed 25 points and was trading at 32838.
Upvote Downvote

 
Market Update: RIL, Bharti Airtel top Nifty gainers; Eicher Motors down over 2%, Infosys most active

2017-12-05 moneycontrol
The Indian benchmark indices on Tuesday afternoon were still trading on a negative note with the Nifty down 42 points or 0.42 percent while the Sensex shed 141 points and was trading at 32727.
Upvote Downvote

 
Market Update: Infosys, Zee gains 2-3%; Jubilant Food jumps over 5%; UPL, Coal India top losers

2017-12-04 moneycontrol
The Indian benchmark indices on Monday afternoon were trading on a positive note with the Nifty up 10.85 points or 0.11 percent while the Sensex added 52 points and was trading at 32885.
Upvote Downvote

 
Market Update: Biocon hits new 52-week high after jumping 10%; Infosys gains 3%, HDFC, SBI most active

2017-12-04 moneycontrol
The Indian benchmark indices on Monday afternoon were trading on a positive note with the Nifty up 21 points or 0.21 percent while the Sensex added 79 points and was trading at 32912.
Upvote Downvote

 
Abbott India shares surge over 12% on Q2 profit

2017-11-13 moneycontrol
Shares of drug firm Abbott India on Monday soared over 12 percent after the company reported 83.31 percent jump in net profit for the September quarter.
Upvote Downvote

 
Closing Bell: Selling pressure grips Sensex as it ends 281 pts lower; Nifty below 10,250

2017-11-13 moneycontrol
3:30 pm Market at Close: Selling pressure in the final hour of trade dragged the market lower, with the Sensex closing over 250 points lower, while the Nifty closed below 10,250-mark.
Upvote Downvote

 
Abbott India Q2 profit rises 83% to Rs137.52 crore

2017-11-13 livemint
New Delhi: Drug firm Abbott India on Monday reported 83.31% jump in net profit to Rs137.52 crore for the September quarter on account of robust sales.
Upvote Downvote

 
Abbott India Q2 net surges 83% at Rs 138 cr on robust sales

2017-11-13 business-standard
Drug firm Abbott India today reported 83.31 per cent jump in net profit to Rs 137.52 crore for the September quarter on account of robust sales. It had posted a net profit of Rs 75.02 crore for the corresponding period of last fiscal, Abbott India said in a filing to BSE.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...